Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications

admin HEALTH NEWS Leave a Comment

Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications Biothera’s Imprime PGG and Merck’s anti-PD-1 inhibitor KEYTRUDA® (pembrolizumab) to be evaluated in combination for patients with either advanced melanoma or metastatic triple negative breast cancer (TNBC) Under previous agreement, Big Ten Cancer Research Consortium (BTCRC) plans to initiate a Phase 1b/2 Imprime PGG/KEYTRUDA trial …